Abstract
The correlation between T-cell infiltration and EOC survival suggests that EOC may be sensitive to adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL). Carboplatin-paclitaxel chemotherapy (CPC) lowers the number of tumor induced immune suppressive myeloid cells, creating a window-of-opportunity for TILs to exert their effective anti-tumor response. IFNα supports TIL. A phase I/II trial (NCT04072263) was initiated to study the feasibility and safety of TIL during CPC +/- IFNα in patients with recurrent platinum sensitive EOC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
